1615250-09-3

Basic information

• Product Name: tert-butyl ((R)-1-((R)-3-(4-methylbenzoyl)thiazolidine-4-carbonyl) piperidin-3-yl)methylcarbamate
• Synonyms: tert-butyl ((R)-1-((R)-3-(4-methylbenzoyl)thiazolidine-4-carbonyl) piperidin-3-yl)methylcarbamate
• CAS NO: 1615250-09-3
• Molecular Weight: 447.599
• Mol File: 1615250-09-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl ((R)-1-((R)-3-(4-methylbenzoyl)thiazolidine-4-carbonyl) piperidin-3-yl)methylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((R)-1-((R)-3-(4-methylbenzoyl)thiazolidine-4-carbonyl) piperidin-3-yl)methylcarbamate(1615250-09-3)
• EPA Substance Registry System: tert-butyl ((R)-1-((R)-3-(4-methylbenzoyl)thiazolidine-4-carbonyl) piperidin-3-yl)methylcarbamate(1615250-09-3)

Safety Data

• Hazardous Substances Data: 1615250-09-3(Hazardous Substances Data)

Upstream product

• 874-60-2 4-methyl-benzoyl chloride 
• 1016167-99-9 (S)-1-piperidin-3-ylmethylcarbamic acid tert-butyl ester 
• 1281533-06-9 C₁₂H₁₃NO₃S 

Relevant articles and documents

Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation

A series of chiral lactam carboxamides of aminomethylpiperidine were synthesized and investigated for the collagen induced in vitro anti-platelet efficacy and collagen plus epinephrine induced in vivo pulmonary thromboembolism. The compound 31a (30 μM/kg) displayed a remarkable antithrombotic efficacy (60% protection) which was sustained for more than 24 h and points to its excellent bioavailability. The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro. Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation. The pharmacokinetic study of 31a indicated very faster absorption, prolonged and constant systemic exposure and thereby exhibiting better therapeutic response.